Vascular Gene Delivery

Introduction

Vascular transplants, a frequently used method to treat some diseases, suffer from a high failure rate, resulting in a significant unmet treatment need. In this connection, Genetronics' technology may help prevent rejection or obstruction of newly implanted vessels and increasing the number of long-lasting vascular transplants. Genetronics has shown in numerous pre-clinical studies that electroporation, a method free of the unwanted side effects associated with viral gene delivery technologies, can effectively facilitate intracellular delivery and dramatically improve uptake of such genes.

Genetronics Biomedical Corporation is a late stage biodmedical company focused on building an oncology franchise based on its proprietary electroporation therapy. The therapy targets a significant unmet clinical need: the selective killing of cancer cells and local ablation of solid tumors while preserving healthy tissue. The company is moving its lead product, the MedPulser(R) Electroporation Therapy System, through pre-marketing studies for head and neck cancer in Europe, where it has CE Mark accreditation, and a US Phase III pivotal study for recurrent head and neck cancer. Merck, Chiron, the US Navy, Vical and other partners are also employing Genetronics' electroporation technology, which enhances local delivery of drugs and DNA, in their developments of novel DNA vaccines and gene therapies.

Source

Wista Innovation